221 related articles for article (PubMed ID: 35851311)
21. Computational design of the affinity and specificity of a therapeutic T cell receptor.
Pierce BG; Hellman LM; Hossain M; Singh NK; Vander Kooi CW; Weng Z; Baker BM
PLoS Comput Biol; 2014 Feb; 10(2):e1003478. PubMed ID: 24550723
[TBL] [Abstract][Full Text] [Related]
22. Engineering soluble T-cell receptors for therapy.
Robinson RA; McMurran C; McCully ML; Cole DK
FEBS J; 2021 Nov; 288(21):6159-6173. PubMed ID: 33624424
[TBL] [Abstract][Full Text] [Related]
23. Systematic mutagenesis of TCR complementarity-determining region 3 residues: a single conservative substitution dramatically improves response to both multiple HLA-DR alleles and peptide variants.
Brawley JV; Concannon P
J Immunol; 1999 Nov; 163(9):4946-52. PubMed ID: 10528198
[TBL] [Abstract][Full Text] [Related]
24. A library of cancer testis specific T cell receptors for T cell receptor gene therapy.
de Rooij MAJ; Remst DFG; van der Steen DM; Wouters AK; Hagedoorn RS; Kester MGD; Meeuwsen MH; Wachsmann TLA; de Ru AH; van Veelen PA; Verdegaal EME; Falkenburg JHF; Heemskerk MHM
Mol Ther Oncolytics; 2023 Mar; 28():1-14. PubMed ID: 36589698
[TBL] [Abstract][Full Text] [Related]
25. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
26. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
27. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.
Cameron BJ; Gerry AB; Dukes J; Harper JV; Kannan V; Bianchi FC; Grand F; Brewer JE; Gupta M; Plesa G; Bossi G; Vuidepot A; Powlesland AS; Legg A; Adams KJ; Bennett AD; Pumphrey NJ; Williams DD; Binder-Scholl G; Kulikovskaya I; Levine BL; Riley JL; Varela-Rohena A; Stadtmauer EA; Rapoport AP; Linette GP; June CH; Hassan NJ; Kalos M; Jakobsen BK
Sci Transl Med; 2013 Aug; 5(197):197ra103. PubMed ID: 23926201
[TBL] [Abstract][Full Text] [Related]
28. Tuning T cell receptor sensitivity through catch bond engineering.
Zhao X; Kolawole EM; Chan W; Feng Y; Yang X; Gee MH; Jude KM; Sibener LV; Fordyce PM; Germain RN; Evavold BD; Garcia KC
Science; 2022 Apr; 376(6589):eabl5282. PubMed ID: 35389803
[TBL] [Abstract][Full Text] [Related]
29. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
[TBL] [Abstract][Full Text] [Related]
30. T-cell Receptors Engineered
Sharma P; Harris DT; Stone JD; Kranz DM
Cancer Immunol Res; 2019 Dec; 7(12):2025-2035. PubMed ID: 31548259
[TBL] [Abstract][Full Text] [Related]
31. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy.
Soon CF; Zhang S; Suneetha PV; Antunes DA; Manns MP; Raha S; Schultze-Florey C; Prinz I; Wedemeyer H; Sällberg Chen M; Cornberg M
Front Immunol; 2019; 10():2076. PubMed ID: 31552033
[TBL] [Abstract][Full Text] [Related]
33. Structural basis of T cell receptor specificity and cross-reactivity of two HLA-DQ2.5-restricted gluten epitopes in celiac disease.
Ciacchi L; Farenc C; Dahal-Koirala S; Petersen J; Sollid LM; Reid HH; Rossjohn J
J Biol Chem; 2022 Mar; 298(3):101619. PubMed ID: 35065967
[TBL] [Abstract][Full Text] [Related]
34. Highly divergent T-cell receptor binding modes underlie specific recognition of a bulged viral peptide bound to a human leukocyte antigen class I molecule.
Liu YC; Miles JJ; Neller MA; Gostick E; Price DA; Purcell AW; McCluskey J; Burrows SR; Rossjohn J; Gras S
J Biol Chem; 2013 May; 288(22):15442-54. PubMed ID: 23569211
[TBL] [Abstract][Full Text] [Related]
35. Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy.
Sanderson JP; Crowley DJ; Wiedermann GE; Quinn LL; Crossland KL; Tunbridge HM; Cornforth TV; Barnes CS; Ahmed T; Howe K; Saini M; Abbott RJ; Anderson VE; Tavano B; Maroto M; Gerry AB
Oncoimmunology; 2020; 9(1):1682381. PubMed ID: 32002290
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.
Linette GP; Stadtmauer EA; Maus MV; Rapoport AP; Levine BL; Emery L; Litzky L; Bagg A; Carreno BM; Cimino PJ; Binder-Scholl GK; Smethurst DP; Gerry AB; Pumphrey NJ; Bennett AD; Brewer JE; Dukes J; Harper J; Tayton-Martin HK; Jakobsen BK; Hassan NJ; Kalos M; June CH
Blood; 2013 Aug; 122(6):863-71. PubMed ID: 23770775
[TBL] [Abstract][Full Text] [Related]
37. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/γcnull mice.
Shirakura Y; Mizuno Y; Wang L; Imai N; Amaike C; Sato E; Ito M; Nukaya I; Mineno J; Takesako K; Ikeda H; Shiku H
Cancer Sci; 2012 Jan; 103(1):17-25. PubMed ID: 21951605
[TBL] [Abstract][Full Text] [Related]
38. A molecular basis underpinning the T cell receptor heterogeneity of mucosal-associated invariant T cells.
Eckle SB; Birkinshaw RW; Kostenko L; Corbett AJ; McWilliam HE; Reantragoon R; Chen Z; Gherardin NA; Beddoe T; Liu L; Patel O; Meehan B; Fairlie DP; Villadangos JA; Godfrey DI; Kjer-Nielsen L; McCluskey J; Rossjohn J
J Exp Med; 2014 Jul; 211(8):1585-600. PubMed ID: 25049336
[TBL] [Abstract][Full Text] [Related]
39. Structure-guided stabilization of pathogen-derived peptide-HLA-E complexes using non-natural amino acids conserves native TCR recognition.
Barber C; De Souza VA; Paterson RL; Martin-Urdiroz M; Mulakkal NC; Srikannathasan V; Connolly M; Phillips G; Foong-Leong T; Pengelly R; Karuppiah V; Grant T; Dembek M; Verma A; Gibbs-Howe D; Blicher TH; Knox A; Robinson RA; Cole DK; Leonard S
Eur J Immunol; 2022 Apr; 52(4):618-632. PubMed ID: 35108401
[TBL] [Abstract][Full Text] [Related]
40. Structural basis for clonal diversity of the human T-cell response to a dominant influenza virus epitope.
Yang X; Chen G; Weng NP; Mariuzza RA
J Biol Chem; 2017 Nov; 292(45):18618-18627. PubMed ID: 28931605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
